William D. Freeman, M.D.

The purpose of this study is to create a large, well annotated speech-bank which can be used in artificial intelligence (AI) projects.

The purpose of this study is to assess the efficacy and safety of PPF-block to mitigate opiod use requirements and improve headache pain control in patients with aneurysmal SAH.

The purpose of this study is to determine if surgical clot reduction after ICH reduces the risk of progressive cognitive decline. Also, to determine if there is a long-term benefit in survival and functional outcome from minimally invasive surgery whether or not cognitive decline occurs.

The purpose of this study is to identify important physiologic trends in bedside ICU data such as cerebral perfusion pressure (CPP), intracranial pressure (ICP) using a bedside “Multimodal monitoring” (MMM) computer which utilizes ICM+ Cambridge software.

This is a randomized, double-blind, placebo-controlled parallel group outpatient study that will utilize standard stroke rehabilitation outcome measures, as well as fMRI techniques in a subset of subjects, to evaluate the effect of HT-3951 on motor recovery and behavior in medically stable subjects following ischemic stroke.

The purpose of this study is to evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.

The purpose of this study is to assess the effectiveness, safety, tolerability, and pharmacokinetics (PK) of elezanumab in subjects with acute ischemic stroke to potentially accelerate recovery and/or provide more complete recovery by decreasing neuronal damage and enhancing restoration of neuronal activity. 

The specific aims of this study are to:

1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset.
2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the subjects' quality of life as measured by EuroQol at 3 months.
3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of hematoma expansion (defined as increase from baseline hematoma volume of > 33%) and in the change from baseline peri-hematoma volume at 24 hours on the serial computed tomographic (CT) scans.
4. Assess the safety of the intensive treatment relative to the standard treatment in the proportion of subjects with treatment-related serious adverse events (SAEs) within 72 hours.

C3FIT’s overall goal is to assess if patient outcomes are improved when the Comprehensive and Primary Stroke Center (CSC/PSC) system is supplemented with an Integrated Stroke Practice Unit (ISPU) system of care, a patient-centric model of care involving the patient and caregiver/family that coordinates care from the acute management through the rehabilitation and recovery of the patient.

The overall objective of this Phase III clinical trial is to obtain information from a population of 500 ICH subjects with intraventricular hemorrhage (IVH), representative of current clinical practice and national demographics of ICH regarding the benefit (or lack thereof) of IVH clot removal on subject function as measured by modified Rankin Scale (mRS). This application requests funding for five years to initiate a Phase III randomized clinical trial (RCT) testing the benefit of clot removal for intraventricular hemorrhage. The investigators propose to compare extraventricular drainage (EVD) use plus recombinant tissue plasminogen activator (rt-PA; Alteplase; Genentech, Inc., San Francisco, CA and Boehringer Ingelheim, Inc., Ingelheim, Germany) with EVD+ placebo in the management and treatment of subjects with small intracerebral hemorrhage (ICH) and large intraventricular hemorrhage (IVH defined as ICH < 30 cc and obstruction of the 3rd or 4th ventricles by intraventricular blood clot).

Study summary:

The overall plan for this study is to conduct qualitative interviews among 40 family members of patients who have been hospitalized in a coma. Subjects for this study will be recruited by local site P.I.s from intensive care units at the following 18 U.S. centers:

All interviews will be conducted virtually via video conferencing by study staff at the Yale School of Medicine and Massachusetts General Hospital. All study activities following the interviews, including data analysis and manuscript writing, will take place at the Yale School of Medicine and Massachusetts General Hospital. We expect this study to be completed by December 31, 2021.

Hypothesis, Aims, purpose, or objectives and Background:

(Include relevant experience, gaps in current knowledge, preliminary data, etc.): 

The purpose of this study is to conduct semi-structured qualitative interviews with caregivers of severely acute brain-injured, incapacitated patients in order to understand specific aspects of their caregiving experience (i.e., emotional coping styles, expectations and understanding of illness, challenges, perceptions of caregiving) and gather information about their preferences for a future psychosocial support intervention (e.g., content, delivery mode [in person vs. secure live video mode], timing). Data from these qualitative interviews will be used to help develop a resiliency-based psychosocial support intervention for caregivers in the future.

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.

The purpose of this study is to determine if cytochrome P450 (CYP) enzyme family variants alter the body's metabolism of nimodipine after Aneurysmal Subarachnoid Hemorrhage (aSAH), and if actual levels of nimodipine correlate with clinical events and patient outcomes.

The purpose is to study the effects of intraventricular nicardipine, a vasodilatory agent, on VP and secondary outcomes of stroke and functional outcome at 30 and 90 days compared to those not treated with this agent.

The purpose of this study is to compare the effectiveness and safety of EG-1962 to the standard of care oral nimodipine for the treatment of adult patients who have an aneurysmal subarachnoid hemorrhage.

The purpose of this study is to test for the long-term outcomes in function for stroke patients who get an early tracheostomy, versus those who have prolonged orotracheal intubation. 

Patients with severe ischemic and hemorrhagic strokes, who require mechanical ventilation, have a particularly bad prognosis. If they require long-term ventilation, their orotracheal tube needs to be, like in any other intensive care patient, replaced by a shorter tracheal tube below the larynx. This so called tracheostomy might be associated with advantages such as less demand of narcotics and pain killers, less lesions in mouth and larynx, better mouth hygiene, safer airway, more patient comfort and earlier mobilisation. The best timepoint for tracheostomy in stroke, however, is not known. Preliminary data from a pilot study of early tracheostomy in patients with hemorrhagic or ischemic stroke suggest that such patients may also have improved survival and long-term functional outcomes, but a large, multicenter clinical trial is needed to confirm these findings.

The purpose of this study is to assess the effectiveness of the Better Mobile Health App for use by patients after hospital discharge for a stroke by using satisfaction survey ratings and hospital readmission rates. The Better App provides a personal health assistant who assists in coordination of care. The app is provided in addition to standard care and compared to the use of standard care alone.